Security Snapshot

Syndax Pharmaceuticals Inc - Common Stock (SNDX) Institutional Ownership

CUSIP: 87164F105

13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

226

Shares (Excl. Options)

99,896,230

Price

$21.01

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
SNDX on Nasdaq
Shares outstanding
88,260,257
Price per share
$23.36
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
99,896,230
Total reported value
$2,098,437,584
% of total 13F portfolios
0.01%
Share change
-2,696,923
Value change
-$24,374,722
Number of holders
226
Price from insider filings
$23.36
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • SNDX - Syndax Pharmaceuticals Inc - Common Stock is tracked under CUSIP 87164F105.
  • 226 institutions reported positions in Q4 2025.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 226 to 47 between Q4 2025 and Q1 2026.
  • Reported value moved from $2,098,437,584 to $80,633,238.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 226 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 87164F105?
CUSIP 87164F105 identifies SNDX - Syndax Pharmaceuticals Inc - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Syndax Pharmaceuticals Inc - Common Stock (SNDX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Kynam Capital Management, LP 10% $113,571,600 8,520,000 Kynam Capital Management, LP 31 Dec 2024
BlackRock, Inc. 7.8% $89,898,173 6,744,049 BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 6.5% +26% $51,576,091 +$9,897,509 5,581,828 +24% THE GOLDMAN SACHS GROUP, INC. 30 Jun 2025
STATE STREET CORP 5.3% $96,527,592 4,596,552 STATE STREET CORPORATION 31 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC 5% $104,118,860 4,457,143 Vanguard Capital Management 31 Mar 2026
Point72 Asset Management, L.P. 5% +77% $44,621,185 +$20,827,520 4,327,952 +88% Point72 Asset Management, L.P. 15 Aug 2025
MORGAN STANLEY 2.4% -65% $27,193,373 -$44,284,339 2,040,013 -62% Morgan Stanley 31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP 0% $475,628 35,681 Wellington Management Group LLP 28 Feb 2025

As of 31 Dec 2025, 226 institutional investors reported holding 99,896,230 shares of Syndax Pharmaceuticals Inc - Common Stock (SNDX). This represents 113% of the company’s total 88,260,257 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Syndax Pharmaceuticals Inc - Common Stock (SNDX) together control 83% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 9.3% 8,239,002 -4.5% 0% $173,101,429
Kynam Capital Management, LP 9.1% 8,050,959 -5.5% 11% $169,150,649
VANGUARD GROUP INC 7.1% 6,230,334 +21% 0% $130,899,317
GOLDMAN SACHS GROUP INC 6.5% 5,695,375 +3.8% 0.02% $119,659,829
Point72 Asset Management, L.P. 5.5% 4,882,053 +15% 0.16% $102,571,934
BANK OF AMERICA CORP /DE/ 5.3% 4,710,746 +27% 0.01% $98,972,773
STATE STREET CORP 5.2% 4,596,552 +19% 0% $96,573,558
Eversept Partners, LP 3.8% 3,314,408 -4.4% 3.9% $69,635,712
FRANKLIN RESOURCES INC 2.7% 2,421,666 +1.3% 0.01% $50,879,210
KINGDON CAPITAL MANAGEMENT, L.L.C. 2.7% 2,350,000 -6% 7.6% $49,373,500
Hood River Capital Management LLC 2.6% 2,316,553 0.53% $48,670,779
Soleus Capital Management, L.P. 2.5% 2,247,110 +12% 2% $47,211,781
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,090,932 -0.02% 0% $43,938,032
Elmind Capital, LP 2.1% 1,855,000 0% 12% $38,973,550
Ensign Peak Advisors, Inc 1.8% 1,598,544 +98% 0.06% $33,585,409
Nuveen, LLC 1.7% 1,483,002 +0.49% 0.01% $31,157,872
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.6% 1,375,681 +11% 0.03% $28,903,000
STEMPOINT CAPITAL LP 1.5% 1,339,379 -2% 4.8% $28,140,353
MPM BIOIMPACT LLC 1.5% 1,337,702 -2.8% 3.2% $28,105,119
Aisling Capital Management LP 1.5% 1,316,806 0% 5.8% $27,666,094
Woodline Partners LP 1.4% 1,250,668 -19% 0.1% $26,276,535
EVENTIDE ASSET MANAGEMENT, LLC 1.4% 1,238,196 +25% 0.41% $26,014,313
D. E. Shaw & Co., Inc. 1.4% 1,219,609 +13% 0.02% $25,623,986
Catalio Capital Management, LP 1.4% 1,196,807 -26% 4.7% $25,144,915
TWO SIGMA INVESTMENTS, LP 1.3% 1,146,936 +61% 0.04% $24,097,125

Institutional Holders of Syndax Pharmaceuticals Inc - Common Stock (SNDX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 3,450,021 $80,633,238 -$9,045,315 $23.36 47
2025 Q4 99,896,230 $2,098,437,584 -$24,374,722 $21.01 226
2025 Q3 101,125,579 $1,555,833,342 +$19,170,271 $15.38 226
2025 Q2 101,743,087 $952,765,629 -$3,412,831 $9.36 214
2025 Q1 100,841,762 $1,238,937,353 +$32,280,128 $12.28 215
2024 Q4 98,036,463 $1,295,985,057 +$87,204,107 $13.22 214
2024 Q3 88,967,889 $1,713,503,490 +$22,962,287 $19.25 208
2024 Q2 87,359,094 $1,793,463,324 -$71,085,162 $20.53 195
2024 Q1 90,291,619 $2,148,803,982 +$45,990,918 $23.80 188
2023 Q4 88,660,945 $1,915,962,261 +$405,830,138 $21.61 176
2023 Q3 71,017,590 $1,031,468,287 -$1,236,482 $14.52 174
2023 Q2 70,660,286 $1,478,899,897 -$48,383,346 $20.93 165
2023 Q1 72,989,203 $1,541,067,785 +$23,662,697 $21.12 161
2022 Q4 71,468,832 $1,818,847,118 +$262,720,878 $25.45 159
2022 Q3 59,986,014 $1,441,473,166 +$97,845,580 $24.03 136
2022 Q2 55,225,664 $1,062,543,225 +$21,478,133 $19.24 116
2022 Q1 54,572,890 $948,388,792 -$36,428,045 $17.38 136
2021 Q4 52,428,774 $1,146,955,026 +$54,297,905 $21.89 129
2021 Q3 49,078,197 $938,007,416 -$20,732,602 $19.11 121
2021 Q2 50,204,902 $861,938,071 +$12,311,173 $17.17 113
2021 Q1 48,482,656 $1,083,969,550 +$46,478,159 $22.36 130
2020 Q4 46,493,166 $1,034,139,433 +$269,937,051 $22.24 140
2020 Q3 34,234,622 $505,296,990 +$23,535,263 $14.76 98
2020 Q2 32,648,161 $483,839,331 +$177,178,450 $14.82 96
2020 Q1 20,764,120 $227,777,510 +$45,430,574 $10.97 81
2019 Q4 16,674,566 $146,400,674 -$3,736,906 $8.78 71
2019 Q3 17,141,763 $128,044,931 -$811,927 $7.47 72
2019 Q2 17,174,052 $159,885,671 +$3,968,740 $9.31 71
2019 Q1 16,955,330 $89,016,913 +$8,086,878 $5.25 66
2018 Q4 15,460,307 $68,794,733 -$2,725,288 $4.45 73
2018 Q3 15,338,464 $123,912,664 +$3,406,829 $8.08 73
2018 Q2 15,085,582 $105,898,739 -$23,251,843 $7.02 83
2018 Q1 17,173,123 $244,377,218 +$5,182,148 $14.23 72
2017 Q4 17,172,317 $150,421,862 +$15,929,302 $8.76 77
2017 Q3 15,034,508 $175,968,675 -$8,293,783 $11.70 67
2017 Q2 15,705,504 $219,397,678 +$56,766,148 $13.97 63
2017 Q1 11,652,824 $159,872,123 +$30,204,104 $13.72 62
2016 Q4 11,123,178 $79,752,466 -$4,867,203 $7.17 55
2016 Q3 11,599,012 $175,841,071 +$19,928,095 $15.16 45
2016 Q2 10,263,556 $101,043,565 +$10,817,957 $9.85 46
2016 Q1 9,443,951 $125,631,000 +$125,631,000 $13.32 27
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .